Asimov, Inc.


STEX25
Active dates:

May 1, 2018 - May 1, 2018
STEX25
STEX25 Participation:
May 1, 2018 - October 31, 2019
Company information

700 Main Street
Cambridge, Massachusetts 02139
United States

Elevator Pitch

Elevator Pitch

Living cells naturally perform remarkable feats of biochemical computation, but this capability is absent from biotechnology. Future applications in therapeutics, manufacturing, and agriculture will require the ability to program cells with new sense-and-response functions. We built a cell design platform called Cello that automatically compiles a DNA sequence from a high-level input/output specification. Using this platform, we are developing previously-impossible biotechnology applications.
Description

Description

Asimov's technology is a synthetic biology CAD platform (Cello) that we developed at MIT to program living cells with "genetic circuits". We have used it to design the most complex sense-and-response cell behaviors to date. We are now extending the platform to build genetic control modules for cell therapies and improved biologics manufacturing.